News | Guidewires | May 30, 2017

Canadian Cardiologist Publishes World-First Mitral Regurgitation Procedure

MitraClip device inserted through jugular vein of 86-year-old patient with SupraCross RF Solution from Baylis Medical Co. Inc.

May 30, 2017 — A Canadian cardiologist has published a report in the journal Eurointervention describing how he used a Canadian-invented device for the first time in the world to successfully insert a MitraClip through a patient's jugular vein rather than the femoral vein.

When Neil Fam, M.D., examined his 86-year-old patient with severe mitral regurgitation — a condition in which the blood flows backward into the heart after it contracts — his options for treating her were limited.

Because of her age and overall health, Ortensia Aceti of Sault Ste. Marie, Ont., was not a good candidate for surgery to repair her mitral valve. She had been in and out of hospital with heart failure and medication was no longer controlling her symptoms.

Instead, he decided on a catheter-based treatment to guide a MitraClip device to the heart and clamp the leaky valve. The catheter would usually be inserted through the femoral vein in the leg, but her vein was blocked.

"We were locked out, blocked from accessing her heart," said Fam, an interventional cardiologist and director of the Cardiac Intensive Care Unit of St. Michael's Hospital in Toronto.

Fam recalled a conversation he had about a year previously with Baylis Medical Co. Inc., a Canadian supplier of high-tech cardiology equipment, about one of their devices that was designed to achieve access to the heart from alternative approaches.

For the first time in the world, Fam successfully used the company's SupraCross RF Solution to guide a MitraClip device through the jugular vein — a more direct route to the heart — and successfully repair Aceti's leaking mitral valve.

Fam said this was possible, despite the awkward angle of the jugular vein in relation to the heart, because the tip of the sheath is steerable and the wire is equipped to deliver radiofrequency energy to puncture the septum of the heart. This allows the physician to position the system appropriately from this challenging angle and puncture the septum of the heart in a precise and controlled manner without using excessive force.

Fam said Aceti had no complications and her condition improved, allowing her to be discharged to her home. At a follow-up appointment, she was doing well with no further heart failure.

Fam said that while this procedure would be appropriate for only selected patients, they are high-risk patients for which there may be no other treatment options.

"Given the success of this procedure, the door is open for future studies of the jugular approach for treating the mitral valve," he said.

For more information: www.pcronline.com/eurointervention

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now